e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9, 2010
LifeVantage Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Colorado
|
|
000-30489
|
|
90-0224471 |
|
|
|
|
|
(State or other Jurisdiction of
Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.) |
|
|
|
11545 W. Bernardo Court, Suite 301, San Diego, California
|
|
92127 |
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (858) 312-8000
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
|
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
Item 2.02 |
|
Results of Operations and Financial Conditions |
On November 9, 2010, Lifevantage Corporation issued a press release announcing its unaudited
first quarter fiscal 2011 financial and operating results. The press release is furnished as
Exhibit 99.1 hereto and shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing.
|
|
|
Item 9.01 |
|
Financial Statements and Exhibits |
|
|
|
|
|
|
99.1 |
|
|
Press release dated November 9, 2010. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
Dated: November 9, 2010 |
LifeVantage Corporation
|
|
|
By: |
/s/ Carrie E. McQueen
|
|
|
|
Carrie E. McQueen |
|
|
|
Chief Financial Officer, Secretary & Treasurer |
|
|
exv99w1
Exhibit 99.1
LIFEVANTAGE ANNOUNCES UNAUDITED FIRST QUARTER FISCAL 2011 FINANCIAL AND OPERATING RESULTS
Company Reports $345k Record Operating Profit on Revenue Increase of $4.6 million, or 247%
over Same Quarter Last Year
Conference call scheduled for November 10, 2010 at 1:30pm (Pacific); simultaneous webcast at
www.lifevantage.com
San Diego, CA, November 9, 2010, LifeVantage Corporation (OTCBB: LFVN), the maker of
science-based solutions to oxidative stress, announced unaudited first quarter fiscal 2011
financial and operating results.
The Company recorded approximately $6.4 million net revenue for the three month period ended
September 30, 2010, which represents a $4.6 million, or 247%, increase over net revenue from the
same quarter last fiscal year, and a $2.0 million, or 45%, sequential increase over net revenue
from the fourth fiscal quarter of 2010. The Company also recorded $5.4 million in gross profit,
representing an 84% gross profit margin, an approximate 1% improvement over both first and fourth
fiscal quarters of 2010.
Total operating expenses for the first fiscal quarter 2011 were approximately $5.1 million, which
represents a $525,000, or 12%, increase over operating expenses from the same quarter last fiscal
year, and a $1.1 million, or 27%, sequential increase over operating expenses from the fourth
fiscal quarter of 2010. The increase of $1.1 million over last quarter is due to increased sales
commissions attributed directly to increased revenue, and to higher personnel costs, tied to our
increased support requirements.
Along with recording our highest quarterly net revenue of $6.4 million, the Company is also
reporting record operating income of approximately $345,000 in the first fiscal quarter 2011. This
$345,000 operating profit compares to an operating loss of over $3.0 million for the same quarter
last year and an operating loss of $290,000 for the most recent fourth fiscal quarter 2010. The
improvement of $635,000 in operating income is due to a $1.7 million increase in gross profit
offset by a $1.1 million increase in operating expenses.
We are very pleased with our first quarter results, said David W. Brown, LifeVantage President
and CEO, They reflect the growth we saw at our recent Elite Academy in San Diego, attended by over
1200 distributors. Wed like to thank all of our distributors, customers and employees responsible
for these record results.
Conference Call Information
The Company will hold a conference call on November 10, 2010 at 1:30pm Pacific time (4:30pm Eastern
time) to discuss first fiscal quarter 2011 financial and operating results and provide an update on
its business. David W. Brown, President and Chief Executive Officer, is scheduled to lead the call
and will be joined by Carrie E. McQueen, Chief Financial Officer.
The conference call may be accessed by dialing 888-452-4034 for domestic callers and entering the
pass code 2457343. The webcast will be available live via the Internet by accessing the Investors
section of LifeVantages website at http://www.lifevantage.com/investor-profile.aspx. Replays of
the webcast will be available on LifeVantages website for 30 days and a phone replay will be
available through November 15th, 2010 by dialing 888-203-1112 and entering the pass code
2457343.
About LifeVantage Corporation
LifeVantage Corporation (OTCBB: LFVN) is a dietary supplement company which markets and sells its
products through the network marketing, or multi-level marketing industry, and seeks to enhance
life through anti-aging and wellness products while creating business opportunities. The Company
offers only what it refers to as true products, which are products backed by science, in two
principal categories: a dietary supplement that combats oxidative stress and anti-aging skincare.
LifeVantages centerpiece product is Protandim®, a dietary supplement which has been clinically
proven to reduce the effects of oxidative stress as well as the progressive rate of cellular aging.
The Company also offers LifeVantage TrueScience Anti-Aging Cream, a scientifically-based,
groundbreaking and unique skin care product. For more information, visit www.LifeVantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism,
satisfaction or disappointment with current prospects, as well as words such as believe, hopes,
intends, estimates, expects, projects, plans, anticipates and variations thereof,
identify forward-looking statements, but their absence does not mean that a statement is not
forward-looking. Such forward-looking statements are not guarantees of performance and the
Companys actual results could differ materially from those contained in such statements. These
forward-looking statements are based on the Companys current expectations and beliefs concerning
future events affecting the Company and involve known and unknown risks and uncertainties that may
cause the Companys actual results or outcomes to be materially different from those anticipated
and discussed herein. These risks and uncertainties include, among others, the potential failure or
unintended negative consequences of the implementation of the Companys network marketing sales
channel; the Companys ability to retain independent distributors or to attract new independent
distributors on an ongoing basis; the potential for third party and governmental actions involving
the Companys network marketing sales channel; the potential for product liability claims against
the Company; the risk that government regulators and regulations could adversely affect the
Companys business; future laws or regulations may hinder or prohibit the production or sale of the
Companys existing product and any future products; unfavorable publicity could materially hurt the
Companys business; and the Companys ability to protect its intellectual property rights and the
value of its product. These and other risk factors are discussed in greater detail in the
Companys Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption Risk
Factors, and in other documents filed by the Company from time to time with the Securities and
Exchange Commission. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this document. All forward-looking statements are based on
information currently available to the Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to reflect events or circumstances
after the date of this document, except as required by law.
###
Investor Relations Contact:
Ioana C. Hone
(858) 312-8000 Ext. 4
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
|
|
September 30, |
|
|
|
2010 |
|
|
2009 |
|
Sales, net |
|
$ |
6,443,349 |
|
|
$ |
1,857,997 |
|
Cost of sales |
|
|
1,020,135 |
|
|
|
312,974 |
|
|
|
|
|
|
|
|
Gross profit |
|
|
5,423,214 |
|
|
|
1,545,023 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
Sales and marketing |
|
|
3,410,843 |
|
|
|
2,012,166 |
|
General and administrative |
|
|
1,507,093 |
|
|
|
2,381,156 |
|
Research and development |
|
|
109,793 |
|
|
|
106,892 |
|
Depreciation and amortization |
|
|
50,716 |
|
|
|
53,298 |
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
5,078,445 |
|
|
|
4,553,512 |
|
|
|
|
|
|
|
|
Operating income (loss) |
|
|
344,769 |
|
|
|
(3,008,489 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
Interest expense |
|
|
(1,464,623 |
) |
|
|
(153,701 |
) |
Change in fair value of derivative liabilities |
|
|
1,835,047 |
|
|
|
6,027,736 |
|
|
|
|
|
|
|
|
Total other income |
|
|
370,424 |
|
|
|
5,874,035 |
|
|
|
|
|
|
|
|
Net income |
|
|
715,193 |
|
|
|
2,865,546 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share, basic and diluted |
|
$ |
0.01 |
|
|
$ |
0.05 |
|
|
|
|
|
|
|
|
Weighted average shares, basic |
|
|
63,684,437 |
|
|
|
55,634,601 |
|
Weighted average shares, diluted |
|
|
89,693,864 |
|
|
|
61,841,866 |
|